Camena Bioscience | Rewriting DNA synthesis technology

Опубликовано: 29 Март 2026
на канале: Mercia Asset Management PLC
202
2

Based in Cambridge, Camena Bioscience produces long and complex synthetic genes using a pioneering new technology. Our approach provides a significant advancement in gene synthesis accuracy.

Steve Harvey (CEO and Co-founder) and James Richardson (VP of R&D) talk us through its bespoke product and processes, and how the backing of Mercia Ventures has helped them rapidly scale.